The NIDA Methamphetamine Clinical Trials Group: A strategy to increase clinical trials research capacity

Addiction

Volumn 102, Issue SUPPL. 1, 2007, Pages 107-113

  Elkashef, Ahmed ^a   Rawson, Richard A ^b   Smith, Edwina ^a   Pearce, Valerie ^b   Flammino, Frank ^c   Campbell, Jan ^d   Donovick, Roger ^e   Gorodetzky, Charles ^f   Haning, William ^g   Mawhinney, Joseph ^h   McCann, Michael ⁱ   Weis, Dennis ^j   Williams, Lorie ^k   Ling, Walter ^b   Vocci, Frank ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^e Matrix Institute on Addictions   (United States)

^f IQVIA   (United States)

^g UNIVERSITY OF HAWAII   (United States)

^h South Bay Treatment Center   (United States)

ⁱ Matrix Institute on Addictions   (United States)

^j Department of Addiction Medicine   (United States)

^k NONE   (United States)

more..

Author keywords

Medication; Methamphetamine; Multi site; Pharmacotherapy

Indexed keywords

AMFEBUTAMONE; METHAMPHETAMINE; ONDANSETRON; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG USE; FEMALE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; METHAMPHETAMINE DEPENDENCE; SCORING SYSTEM; SELF REPORT; SUBSTANCE ABUSE; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS;

ADULT; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HUMANS; MALE; METHAMPHETAMINE; PATIENT COMPLIANCE; PILOT PROJECTS; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME;

EID: 33847311289     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2007.01779.x     Document Type: Article

References (16)

1. National Institute on Drug Abuse (NIDA) Community Epidemiology Work Group (CEWG). Epidemiologic Trends in Drug Abuse, 1, Highlights and Executive Summary. Publication no. 01 4916A. Bethesda, MD: NIDA; 2001.
2. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: APA; 1994.
3. National Evaluation Data and Technical Assistance Center (NEDTAC). Epidemiology and Treatment of Methamphetamine Abuse in California: A Regional Report. Contract no. 270-94-001. Rockville, MD: Center for Substance Abuse Treatment; 1998.
4. Office of National Drug Control Policy (ONDCP). Pulse Check. Washington, DC: Executive Office of the President; 2002. Available at: http://www.whitehousedrugpolicy. gov/publications/drugfact/pulsechk/apr02/index. html (accessed 18 March 2005).
5. Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies. Treatment Episode Data Set (TEDS). Highlights - 2002. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-22, DHHS Publication no. (SMA) 04-3946. Rockville, MD: SAMHSA; 2004.
6. National Association of Counties (NACo). The Meth Epidemic in America: Two Surveys of U.S. Counties: the Criminal Effect of Meth on Communities, the Impact of Meth on Children. Washington, DC: NACo; 2005. Available at: http://nwww.Naco.Org/Template.cfm/Section=Surveys (accessed 3 August 2005).
7. NIDA Notes. Director's column. Methamphetamine Abuse and Addiction 13, no. 1. NIDA Research Report, Publication no. PHD, 756. Rockville, MD: National Clearinghouse for Alcohol and Drug Information (NCADI); 1998.
8. First M. B., Spitzer R. L., Gibbon M., Williams J. B. W. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I): Clinician Version. Washington: DC. American Psychiatric Press; c. 1997.
9. McLellan A. T., Kushner H., Metzger D., Peters R., Smith I., Grissom G. et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992;9: 199-213.
10. Williams J. B. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988; 45: 742-7.
11. Rawson R., Obert J., McCann M., Smith D., Scheffey E. The Neurobehavioral Treatment Manual. Beverly Hills, CA: Matrix Institute on Addictions; 1989.
12. Costall B., Jones B. J., Kelly M. E., Naylor R. J., Onaivi E. S., Tyers M. B. Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav 1990; 36: 339-44.
13. Costall B., Jones B. J., Kelly M. E., Naylor R. J., Onaivi E. S., Tyers M. B. Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Pharmacol Biochem Behav 1990; 36: 97-104.
14. King G. R., Xiong Z., Ellinwood E. H. Jr. Blockade of the expression of sensitization and tolerance by ondansetron, a 5-HT3 receptor antagonist, administered during withdrawal from intermittent and continuous cocaine. Psychopharmacology 1998; 135: 263-9.
15. King G. R., Xiong Z., Douglass S., Ellinwood E. H. Jr. Long term blockade of the expression of cocaine sensitization by ondansetron, a 5-HT3 receptor antagonist. Eur J Pharmacol 2000; 394: 97-101.
16. King G. R., Xiong Z., Ellinwood E. H. Jr. Withdrawal from continuous cocaine administration: time dependent changes in nucleus accumbens 5-HT3 receptor function and behavioral tolerance. Psychopharmacology 1999; 142: 352-9.